Search Results

Your search for Thomas E. Stinchcombe, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / September 2019

Does the Addition of Bevacizumab to Erlotinib in Advanced EGFR-Mutant NSCLC Improve PFS?

In a phase II trial reported in JAMA Oncology, Thomas E. Stinchcombe, MD, and colleagues found that the addition of bevacizumab to erlotinib did not significantly improve progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC). Study Details The...

immunotherapy

lung cancer

By Thomas E. Stinchcombe, MD / November 10, 2018

Corticosteroids and Immunotherapy: Guilty or Guilt By Association?

FIRST-LINE TREATMENT options for advanced non–small cell lung cancer (NSCLC) include single- agent immunotherapy for patients with a programmed cell death ligand 1 (PD-L1) tumor proportion score of at least 50% or in combination with chemotherapy in unselected patients.1-3 Single immunotherapy is...

Dec

Today In Oncology

Search Results

Your search for Thomas E. Stinchcombe, MD matches 2 pages

Does the Addition of Bevacizumab to Erlotinib in Advanced EGFR-Mutant NSCLC Improve PFS?

Corticosteroids and Immunotherapy: Guilty or Guilt By Association?

Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

Colorectal Cancer Incidence and Time to Recurrence

Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC

Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors